Home    eJManager.com Add Your Journal   |    Follow on Twitter   |    Subscribe to List

Directory for Medical Articles
 

Open Access

Original Research

RMJ. 2016; 41(3): 280-282


Hematological side effects of pegylated interferon alpha 2a and ribavirin therapy at Sheikh Khalifa Bin Zaid Hospital, Rawalakot, Pakistan

Shazia Siddiq, Faiza Batool, Kausar Malik.

Abstract
Objectives: To observe hematological side effects of pegylated interferon alpha 2a and ribavirin therapy at Sheikh Khalifa Bin Zaid Hospital, Rawalakot, Pakistan.
Methodology: This descriptive study was conducted at the Department of Medicine, Sheikh Khalifa Bin Zaid Hospital, Rawalakot, Pakistan over a period of 2 years. It included 100 patients with chronic hepatitis C and laboratory investigations like blood complete picture, liver function tests (LFTs), Quantitative PCR for HCV RNA and ultrasound abdomen were reviewed. Combination therapy with pegylated interferon alpha 2a and ribavirin was started and patients progress was monitored for 6 months. Their blood complete picture was repeated at 2 weeks, 4 weeks and then on monthly basis for six months.
Results: Out of 100 patients, 68 were females and 32 were male. Mean age was 43 years. Mean hemoglobin, white blood cells (WBC) and platelets before treatment were 12.4 g/dl, 6.8 x 103/mcL and 210 x 103/mcL, respectively. Mean WBC kept on decreasing until 3 months and then improved and at end of treatment were 5.6 x 103/mcL. Similar trend was seen in hemoglobin with mean hemoglobin 11 g/dl at 6 months. Mean platelets at 6 months were 199 x 103/mc (P

Key words: Hematological side effects, pegylated interferon alpha 2a, ribavirin, hepatitis C



Share this Article




ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJManager OJMS
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright © ScopeMedź Information Services.
Scopemed Buttons